1. Ferrer L, Gaillardin F, Cayuela A, Hernando C, Muñoz R, Sánchez N, Forero CG, Ronda E, Casabona J. Estado de salud de personas inmigrantes en Cataluña desde una perspectiva de género: Proyecto PELFI [Health status among immigrant in Catalonia from a gender perspective: PELFI project]. Gac Sanit. 2021 Apr 22:S0213-9111(21)00071-6. doi: 10.1016/j.gaceta.2021.02.010. Epub ahead of print. PMID: 33896656.


2. Ibáñez-Sanz G, Sanz-Pamplona R, Garcia M, On Behalf Of The MSIC-SC Research Group. Future Prospects of Colorectal Cancer Screening: Characterizing Interval Cancers. Cancers (Basel). 2021;13:1328. doi: 10.3390/cancers13061328. PMID: 33809520.


3. Molina-Barceló A, Moreno Salas J, Peiró-Pérez R, Arroyo G, Ibáñez Cabanell J, Vanaclocha Espí M, Binefa G, García M, Salas Trejo D. Desigualdades de acceso a los programas de cribado del cáncer en España y cómo reducirlas: datos de 2013 y 2020 [Inequalities in access to cancer screening programmes in Spain and how to reduce them: data from 2013 and 2020.]. Rev Esp Salud Publica. 2021;95:e202101017. PMID: 33496270.


4. Vives N, Farre A, Ibáñez-Sanz G, Vidal C, Binefa G, Milà N, Pérez-Lacasta MJ, Travier N, Benito L, Espinàs JA, Bagaria G, Garcia M. Text messaging as a tool to improve cancer screening programs (M-TICS Study): A randomized controlled trial protocol. PLoS One. 2021;16:e0245806. doi: 10.1371/journal.pone.0245806. PMID: 33481914.


5. Travier N, Fu M, Romaguera A, Martín-Cantera C, Fernández E, Vidal C, Garcia M; LUCAPREV research group. 6-Year Risk of Developing Lung Cancer in Spain: Analysis by Autonomous Communities. Arch Bronconeumol. 2021.;57:521-527. doi: 10.1016/j.arbres.2020.03.022. PMID: 32402549.


6. Vives N, Milà N, Binefa G, Travier N, Farre A, Vidal C, Sattari M, Bagaria G, Garcia M. Role of community pharmacies in a population-based colorectal cancer screening program. Prev Med. 2021;145:106420. doi: 10.1016/j.ypmed.2021.106420. PMID: 33422578.


7. Pons-Rodríguez A, Martínez-Alonso M, Perestelo-Pérez L, Garcia M, Sala M, Rué M; en nombre del grupo InforMa; El grupo InforMa está formado por. Elección informada en el cribado del cáncer de mama: el papel del nivel educativo [Informed choice in breast cancer screening: the role of education]. Gac Sanit. 2021;35:243-249. doi: 10.1016/j.gaceta.2020.01.002. PMID: 32173050.


8. Román M, Louro J, Posso M, Alcántara R, Peñalva L, Sala M, Del Riego J, Prieto M, Vidal C, Sánchez M, Bargalló X, Tusquets I, Castells X. Breast density, benign breast disease, and risk of breast cancer over time. Eur Radiol. 2021; 31:4839-4847. doi: 10.1007/s00330-020-07490-5. PMID: 33409776.


9. Vernet-Tomás M, Louro J, Román M, Saladié F, Posso M, Prieto M, Vázquez I, Baré M, Peñalva L, Vidal C, Bargalló X, Sánchez M, Ferrer J, A Espinàs J, Quintana MJ, Rodríguez-Arana A, Castells X; BELE study group. Risk of breast cancer two years after a benign biopsy depends on the mammographic feature prompting recall. Maturitas. 2021;144:53-59. doi: 10.1016/j.maturitas.2020.10.024. PMID: 33358209.


10. Ibáñez-Sanz G, Milà N, de la Peña-Negro LC, Garcia M, Vidal C, Rodríguez-Alonso L, Binefa G, Rodríguez-Moranta F, Moreno V. Proton-pump inhibitors are associated with a high false-positivity rate in faecal immunochemical testing. J Gastroenterol. 2021;56:42-53. doi: 10.1007/s00535-020-01738-z. PMID: 33159805.


11. Agustí C, Muñoz R, González V, Villegas L, Fibla J, Meroño M, Capitán A, Fernàndez-López L, Platteau T, Casabona J. Outreach HIV testing using oral fluid and online consultation of the results: Pilot intervention in Catalonia. Enferm Infecc Microbiol Clin. 2021;39:3-8. doi: 10.1016/j.eimc.2020.01.020. PMID: 32151468.


12. Ibáñez-Sanz G, Milà N, Vidal C, Rocamora J, Moreno V, Sanz-Pamplona R, Garcia M; MSIC-SC research group. Positive impact of a faecal-based screening programme on colorectal cancer mortality risk. PLoS One. 2021;16:e0253369. doi: 10.1371/journal.pone.0253369. PMID: 34191813.


13. Posso M, Alcántara R, Vázquez I, Comerma L, Baré M, Louro J, Quintana MJ, Román M, Marcos-Gragera R, Vernet-Tomas M, Saladie F, Vidal C, Bargalló X, Peñalva L, Sala M, Castells X; BELE study group. Mammographic features of benign breast lesions and risk of subsequent breast cancer in women attending breast cancer screening. Eur Radiol. 2021 Jun 22. doi: 10.1007/s00330-021-08118-y. Epub ahead of print. PMID: 34156554.


14. Breast Screening Working Group (WG2) of the Covid-19 and Cancer Global Modelling Consortium, Figueroa JD, Gray E, Pashayan N, Deandrea S, Karch A, Vale DB, Elder K, Procopio P, van Ravesteyn NT, Mutabi M, Canfell K, Nickson C. The impact of the Covid-19 pandemic on breast cancer early detection and screening. Prev Med. 2021;151:106585. doi: 10.1016/j.ypmed.2021.106585. PMID: 34217412.


15. Diaz M, Garcia M, Vidal C, Santiago A, Gnutti G, Gómez D, Trapero-Bertran M on behalf of the Lung Cancer Prevention (LUCAPREV) research group. Health and economic impact at a population level of both primary and secondary preventive lung cancer interventions: a model-based cost-effectiveness analysis. Lung Cancer. 2021;159:153-161. doi:10.1016/j.lungcan.2021.06.027. PMID: 34352591.


16. Louro J, Román M, Posso M, Vázquez I, Saladié F, Rodriguez-Arana A, Quintana MJ, Domingo L, Baré M, Marcos-Gragera R, Vernet-Tomas M, Sala M, Castells X; BELE and IRIS Study Groups. Developing and validating an individualized breast cancer risk prediction model for women attending breast cancer screening. PLoS One. 2021;16(3):e0248930. doi: 10.1371/journal.pone.0248930. PMID: 33755692.


17. Obón-Santacana M, Díez-Villanueva A, Alonso MH, Ibañez-Sanz G, Guinó E, López A, Rodriguez-Alonso L, Mata A, García-Rodríguez A, García Palomo A, Molina AJ, Garcia M, Binefa G, Martín V, Moreno V. Polygenic risk score across distinct colorectal cancer screening outcomes: from premalignant polyps to colorectal cancer. BMC Medicine. 2021 [Accepted]